RESUMEN
BACKGROUND: In settings where general anaesthesia is unnecessary, effective sedation, analgesia and local anaesthesia are crucial for optimal outcomes. Traditionally, sedation have been managed and controlled by healthcare professionals, but advancements in pharmacology and technology have renewed the way we are able to sedate. Patient-controlled sedation (PCS) offers a promising approach, allowing patients to adjust their sedation levels during procedures. This shift aims to enhance sedation quality, improve patient satisfaction and involvement and expedite discharge. METHODS: The search strategy will be crafted in partnership with the Librarian well-versed in scoping reviews. 'Patient controlled sedation' is a wide search. The search will include databases, as MEDLINE/PubMed, EMBASE, Cochrane Central Register of Controlled Trials, CINAHL and Google Scholar. All literature findings will be entered into a web-based screening and data extraction tool. Two independent reviewers will assess the eligibility and inclusion of all studies. The variables to be extracted will encompass trial characteristics, participant characteristics, assessment of PCS, identified risk factors for PCS, and the evaluation of patient satisfaction as assessed in the included studies. RESULTS: Following PRISMA-P and PRISMA-ScR guidelines, this scoping review includes studies of any design. Data synthesis involves descriptive statistics and narrative presentations to explore the relationship between results and objectives. The outcome will be which procedures/surgeries PCS is used for and which patients are eligible for PCS. Additionally, aspects such as patient and operator satisfaction, economical pros and cons adverse effects will be considered. CONCLUSION: The scoping review will aim to give a better understanding of in which settings PCS is used. This scoping review provides a comprehensive understanding of PCS and identifies gaps in the literature to shape future research, so we can ensure the best possible sedation for patients in the future.
RESUMEN
BACKGROUND: Remimazolam, a novel benzodiazepine, shows promise as an alternative to traditional sedatives and hypnotic agents in procedural sedation and general anaesthesia. While preliminary research indicates potential advantages over conventional agents, such as faster onset, predictable duration, and improved safety profile, the extent and quality of existing evidence remain unclear. This scoping review aims to investigate the current clinical role of remimazolam and provide a broad and comprehensive overview. METHODS: The proposed review will adhere to the JBI methodology for scoping reviews and the Preferred Reporting Items for Systematic Review and Meta-Analysis for Scoping Reviews. A comprehensive search will be conducted across major peer-reviewed databases and grey literature will be sought. All studies involving individuals undergoing procedural sedation or general anaesthesia with remimazolam will be eligible. Data extraction will encompass trial and participant characteristics, intervention details, reported outcomes, comparative efficacy versus midazolam and propofol, patient and operator experience and economic costs. RESULTS: We will provide a descriptive summary supplemented by statistics, figures and tables where applicable. CONCLUSION: The outlined scoping review aims to assess the clinical use of remimazolam in procedural sedation and as the hypnotic component of general anaesthesia. The review will map the current body of evidence of remimazolam and identify knowledge gaps, contributing to understanding its clinical implications and guiding future research efforts in procedural sedation and general anaesthesia.